Skip to main content
SpringerLink
Log in

The metabolic fate of2H-labelled propafenone in man

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

An Erratum to this article was published on 01 April 1984

Summary

The metabolism of propafenone was studied in three humans by using 300 mg of the deuterated compound given orally. The excretion of propafenone and its metabolites was assessed by measuring the deuterium content in the excretion products by means of a microwave plasma detector. At selected times the metabolic pattern in plasma, urine, bile and feces was determined. The metabolites were isolated and the structure of the main compounds was characterized.

Propafenone is absorbed completely and quantitatively metabolized. Unchanged propafenone is excreted neither in the urine nor in the feces in amounts of more than 1 % the dose. The percentage of free unconjugated propafenone of the total deuterium content in the plasma was about 10 % 3 and 6 hours after application. Conjugates of hydroxylated derivatives of propafenone are present predominantly in the plasma.

The excretion of the metabolites takes place mainly by way of the feces, 53 % of the dose is excreted by this route within 48 hours. Urinary elimination accounted for 18.5 and 38 % of the dose within 48 hours in two humans.

It was possible to elucidate the structure of 11 metabolites, accounting for more than 90 % of the dose administered. The major metabolites are conjugates of 5-hydroxypropafenone and hydroxy-methoxy-propafenone with glucuronic and sulphuric acid and propafenone glucuronide.

Furthermore, metabolic products of oxydative deamination pathway were identified, i.e. a glycol and a lactic acid derivative. C-C splitting yields a relatively large amount of 3-phenyl-propionic acid, while cleavage of the ether group leads to a phenolic product and is only of minor importance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hege, H.G., Lietz, H. Weymann, J. (1984): Untersuchungen zum Metabolismus von Propafenon Arzneimittel-Forschung (Drug Research), in press.

  2. Hege, H.G., Weymann, J. (1982): in Stable Isotopes, Proceedings of the 4th International Conference, Volume 11 of Analytical Chemistry Symposia Series. Ed.: Schmidt, H.L., Forstel, H., Heinzinger, K. p. 679–684. Elsevier Scientific Publishing Company, Amsterdam, Oxford, New York.

    Google Scholar 

  3. Barlow J.J., Kellie A.E. (1959): Biochem. J.: A quantitative method for the chromatographic separation of 17-Oxo Steroid Sulphates from 17-Oxo-Steroid-Glucuronides71, 86–91.

    CAS  PubMed  Google Scholar 

  4. Brenner, K.S. (1978): Practical experience with a microwave plasma detector. Limits of measurement and examples of applications. J. Chromatogr.167, 365–380.

    Article  CAS  Google Scholar 

  5. Riggs, C.E., Benjamin, R.S., Serpich, A.A., Bachur, N. (1977): Clin. Pharmacol./Therap.: Biliary disposition of adriamycin.22, 234–241.

    Google Scholar 

  6. Blanke, H., Aschbrenner, B., Karsch, K.R., Kreuzer, H. (1979): Dtsch. med. Wschr.: Plasmaspiegel-Wirkungs-Beziehung und Organverteilung von Propafenon104, 587–591.

    CAS  PubMed  Google Scholar 

  7. Fenselau, C., Johnson, L.P. (1980): Drug Metab. Dispos.: Analysis of intact glucuronides by mass spectrometry and gas chromatography- mass spectrometry.8, 274–283.

    CAS  PubMed  Google Scholar 

  8. Hoffmann, K.J., Arfwidsson, A., Borg, K.O. (1982): Drug Metab. Dispos.: The metabolic disposition of the selective β1 agonist prenalterol in mice, rat, dog and humans.10, 173–179.

    CAS  PubMed  Google Scholar 

  9. Garteiz, D.A., Walle, T. (1972): J. Pharm. Sci.: Electron impact fragmentation studies of β-blocking drugs and their metbolites by GC-Mass Spectroscopy.61, 1728–1731.

    Article  CAS  PubMed  Google Scholar 

  10. Walle, T., Oatis, J.E., Walle, U.K., Knapp, D.R. (1982): Drug Metab. Dispos.: New ring-hydroxylated metabolites of propranolol.10, 122–127.

    CAS  PubMed  Google Scholar 

  11. Walle, T., Conradi, E.C., Walle, U.K., Gaffney, T.E. (1978): Drug Metab. Dispos.: O-Methylated catechollike metabolites of propranolol in man.6, 481–487.

    CAS  PubMed  Google Scholar 

  12. Bourne, G.R. «Progress in Drug Metabolism», (J.W. Bridges and L.F. Chasseaud, ed) (1981): p. 77, John Wiley & Sons Ltd.

Download references

Author information

Authors and Affiliations

  1. Biochemical, Knoll AG, Unternehmensbereich Pharma der BASF Aktiengesellschaft, Postfach 210805, 6700, Ludwigshafen/Rhein, GFR

    H. G. Hege & H. Lietz

  2. Human Pharmacology Department, Knoll AG, Unternehmensbereich Pharma der BASF Aktiengesellschaft, Postfach 210805, 6700, Ludwigshafen/Rhein, GFR

    M. Hollmann & S. Kaumeier

Authors
  1. H. G. Hege
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Hollmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kaumeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Lietz
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03189625.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hege, H.G., Hollmann, M., Kaumeier, S. et al. The metabolic fate of2H-labelled propafenone in man. European Journal of Drug Metabolism and Pharmacokinetics 9, 41–55 (1984). https://doi.org/10.1007/BF03189604

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189604

Key words

Search

Navigation